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Medication use by the nursing mothers is a controversial topic, 
with the potential for infants to be exposed via breastmilk. This 
ethical dilemma has led to health professionals, authorities, and 
parents considering infant formula to be a reasonable alternative to 
mitigate risk. As a consequence, there is a lack of evidence about the 
safety and efficacy of many medications during lactation, including 
lithium1. Decisions to use lithium during the perinatal period are 
challenging because information about the efficacy and safety for 
the mother-child dyad come from observational studies of lactation 
outcomes, which have important limitations and biases2,3.
Breastfeeding is an important public health issue because it 
promotes health, prevents disease, and contributes to reducing 
health inequalities in mothers and nursing infants. Breastfeeding is 
also a great benefit to the environment and society4. Human milk 
is uniquely tailored to meet the nutritional needs of human infants, 
including premature and ill newborns. It has the appropriate balance 
of nutrients provided in easily digestible and bioavailable forms. 
Optimal infant and young child feeding practices include exclusive 
breastfeeding for the first 6 months of life, if possible, followed 
by combining breastmilk with adequate, safe, and appropriate 
complementary foods until the infant is at least 1–2 years old5.
According to the US National Centers for Disease Control and 
Prevention, there are few contraindications to breastfeeding. These 
include maternal infection with HIV, human T-cell lymphotropic 
virus type 1 or 2, active untreated tuberculosis, or herpes simplex 
lesions on the breast. Additionally, maternal use of illicit street drugs 
(i.e., phencyclidine or cocaine), chemotherapeutic agents (drugs 
interfering with cell replication), and radioactive isotope therapies 
should contraindicate breastfeeding. Concerning the infants 
themselves, those with galactosemia should not be breastfed6. 
However, a 2012 clinical report by the American Academy of 
Pediatrics7 indicated that most medications and immunizations are 
safe to use during lactation.
A common reason for never starting or for interrupting 
breastfeeding is medication use by the nursing mother. Any 
pharmacologic therapeutic decision during lactation should be 
guided by the best available evidence and the importance of benefit 
for each patient. Factors influencing the decision to breastfeed 
converge around the advantages and risks of breastfeeding for the 
mother and infant, the socio-demographic and clinical features of 
the mother, personal experience and family tradition, the presence 
of a support system (whether professional or partner, family, 
social), and personal choice. The optimal time to explore women’s 
preferences for breastfeeding and to educate the family about 
treatment options during breastfeeding is before they conceive 
or early in pregnancy8. Options include exclusive breastfeeding, 
breastfeeding supplemented with formula, or exclusive formula 
feeding.
Bipolar disorder is a chronic mental illness that affects about 350 
million people worldwide, equating to 3% of the world population. 
It affects men and women in comparable rates, often starting before 
age 25 years, without cultural or ethnic variation9,10. There seems 
to be a higher risk for women to suffer bipolar II (hypomania), 
rapid cycling, and mixed episodes compared with men. Lithium 
use for the treatment of bipolar disorder has been reported since 
late 1940s11 and was approved in 1970 by the US Food and Drug 
Administration (FDA) for the treatment of acute mania and in 
1974 for the long-term maintenance of bipolar disorder. It is also 
prescribed as adjunctive treatment in major depressive disorder 
and for preventing suicidal behavior in patients with affective 
disorders12-13.
Women with bipolar disorder are at high risk of symptom 
relapse during the perinatal period14. Although its use during the 
first trimester has been associated to a dose-dependent increase 
risk of congenital malformations15, it has proven to be an effective 
preventive treatment during perinatal period16. In relation to 
treatment at others stages of life, some peculiarities must be 
considered for the management of lithium treatment during the 
perinatal period. For example, physiological renal changes during 
pregnancy17 may alter the pharmacokinetics of lithium, and its 
serum concentrations will decline throughout pregnancy. This 
necessitates preferably weekly monitoring in the third trimester 
with does adjustment to maintain therapeutic levels18. Lithium 
also has a complete placental passage and equilibrates between 
the maternal and fetal circulation across a wide range of maternal 
concentrations (0.2–2.6 mEq/L)19. It has been shown that neonatal 
serum lithium concentrations >0.64 mEq/L may be associated 
with an increased rate of neonatal complications such a lethargy, 
cyanosis, hypothermia, hypotonia, hypothyroidism, hypoglycemia, 
polyuria, respiratory problems, and poor drinking ability19-20. 
Postpartum, serum lithium concentrations in the mother gradually 
return to their preconception levels, and this presents a risk for 
lithium intoxication if women have had their dose increased during 
pregnancy. Lithium serum concentration should be measured twice 
weekly for the first 2 weeks after delivery and monthly thereafter for 
the next 3–6 months18.
Lithium is a cation that transfers easily into breast milk. The 
recommendations for its use during breastfeeding vary due to the 
high variability of its diffusion into breastmilk, the secondary risk 
of lithium toxicity in the newborn, and the risk of relapse associated 
with sleep deprivation during the period of exclusive maternal 
breastfeeding21. There are limited data about the long-term effects 
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of lithium exposure via breastmilk, but it does seem that the risk 
of serious adverse events in the nursing infants is relatively low7. 
Two recent systematic reviews concerning clinical lactation and 
lithium showed that exposure of the nursing infant to lithium is less 
during breastfeeding than during pregnancy. However, there was 
also a high degree of heterogeneity between the studies, including 
exposure durations, the presence of polypharmacy, lithium sampling 
times, type of breastfeeding, and age of infants2,3. Nevertheless, it 
is certainly plausible that nursing infants would be vulnerable to 
the same side effects as adults, including changes in thyroid and 
renal functions. In turn, this necessitates regular clinical and blood 
monitoring (e.g., serum lithium, thyroid stimulating hormone, 
blood urea nitrogen, and creatinine) immediately postpartum and 
at regular intervals while breasfeeding22.
Given the many benefits of breastfeeding, some women who 
may also benefit from lithium in the postpartum period are likely 
to consider breastfeeding. The professionals involved in this 
consultation must be adequately trained about the pharmacology 
of lactation8. Women should then have an individualized 
breastfeeding plan drafted in collaboration with perinatal 
psychiatrists, obstetricians, pediatricians, midwives, nurses, and 
family physicians. Research in international collaborative networks 
would be interesting to increase current evidence to support women 
in achieving their breastfeeding goals.
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